Please login to the form below
RA
This page shows the latest RA news and features for those working in and with pharma, biotech and healthcare.
Gilead’s Jyseleca is given a NICE recommendation for rheumatoid arthritis
In phase 3 trials, Jyseleca was shown to be effective in reducing the symptoms of RA, including joint tenderness and swelling. ... FINCH 3 compared Jyseleca alone or in combination with methotrexate as a front-line therapy for patients with
Latest news
-
The best work in healthcare communications shines at virtual Communiqué Awards
3.Excellence in Global Education Meetings/Stand-Alone Events. Sponsored by HEALTH UNLIMITED. Winner: LiBRA 2019: Looking Beyond the Joint in Rheumatoid Arthritis (RA): Is There a Missing Link in RA
-
AbbVie’s JAK inhibitor Rinvoq approved in EU for rheumatoid arthritis
The pharma company has been pushing Rinvoq (upadacitinib) into the RA market, while its Boehringer Ingelheim-partnered drug Skyrizi (risankizumab) has been making headway in psoriasis. ... ICER also presented concerns over the long-term impact of
-
AbbVie scores FDA approval for arthritis treatment upadacitinib
AbbVie has been betting on its new products upadacitinib for RA and Skyrizi for psoriasis to combat Humira’s decline. ... If approved in Europe, AbbVie could begin to reclaim Humira’s lost ground in RA.
-
Gilead strikes $5.1bn deal to bolster ties with Galapagos
Filgotinib is however up against some tough competition in the market, from Pfizer’s blockbuster Xeljanz (tofacitinib) – already approved for RA, psoriatic arthritis and ulcerative colitis – as well as AbbVie’s ... well-regarded JAK1 inhibitor
-
Citryll snares €15m backing for its autoimmune disease NETs
New approach to tackling diseases such as lupus, RA. Dutch biotech Citryll has raised 15m ($17m) in first-round financing to help advance its new therapeutic approach to autoimmune diseases.
More from news
Approximately 9 fully matching, plus 152 partially matching documents found.
Latest Intelligence
-
Drug launches to watch in 2019
The good news for the company is that it has not one but two potential blockbusters likely to gain approval in 2019: Upadacitinib (AbbVie) for RA and risankizumab (co-marketed with ... Likewise, upadacitinib will face competition in both RA and atopic
-
Deal Watch January 2018
Royalty monetisation. 230. Jiangsu Hengrui Medicine/Arcutis. SHR0302, selective JAK inhibitor, for dermatology disorders (currently p2 for RA in China).
-
European CTR implementation advances ethical assessment of clinical trials
Timelines are becoming stricter with regard to the fact that compatibility with Regulatory Authority (RA) assessment must be ensured. ... Per the 2001/20/EC directive, assessment was independent from RA and this rule has created more flexibility for EC
-
Behavioural design - it's a no-brainer
Let's start with rheumatoid arthritis. Fatal medication errors relating to a disease-modifying medication for RA prompted an investigation into patient behaviour.
-
Deal Watch December 2015
Galapagos (NL). Gilead. Collaboration. licence. JAK1-selective inhibitor, filgotinib in phase II for RA and Crohn's disease .
More from intelligence
Approximately 0 fully matching, plus 22 partially matching documents found.
Latest from PMHub
-
The other side of … rheumatoid arthritis
So when blood tests came back normal, she felt confident to pursue referral until RA was confirmed.
-
Lucid Group reaches the finals of the PM360 2020 Trailblazer Initiative Awards
LiBRA is a multichannel program, focused on inspiring and enabling clinical behavior change to achieve better disease control for patients with RA. ... Lisa Druce, Managing Director, Lighthouse Medical Communications US, commented “RA is a chronic
-
Lucid Group scoop a win and a high commendation at Communiqué 2020
Its programme – ‘LiBRA 2019: Looking beyond the joint in rheumatoid arthritis (RA): Is there a missing link in RA management?’ – won the category, with a high commendation going to ‘CLEAR HORIZONS –
-
Lucid Group are shortlisted in three categories for Communiqué 2020
LiBRA 2019: Looking beyond the joint in rheumatoid arthritis (RA): Is there a missing link in RA management?
-
WHITE PAPER: Patient nonadherence – the $637bn paradox
Geneva:. World Health Organisation; 2003. 7. Ward BW, Schiller JS, Goodman RA. ... Yugoslavia: discussion paper. J R Soc Med 1991; 84:288–291. 27. Boza RA, Milanes F, Slater V, Garrigo L, Rivera CE.
More from PMHub
Approximately 2 fully matching, plus 28 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Account Manager Healthcare / Pharmaceutical Sector
-
Negotiable Salary
-
Healthcare Account Director
-
Competitive
-
Healthcare Senior Account Manager
-
Competitive
- Sales Director, Healthcare communications agency, London/ SE UK
-
Six figure salary
-
Medical Editor
-
Competitive
-
Healthcare Lead Copywriter
-
Competitive
- Lilly’s antibody bamlanivimab cuts COVID-19 risk by up to 80%
- BMS gains FDA approval for second Opdivo combo in kidney cancer
- Inovio plans late-stage COVID-19 vaccine study in second quarter 2021
- Sanofi, GSK delay COVID-19 vaccine trial after underwhelming results in elderly participants
- Pfizer/BioNTech's COVID-19 vaccine found to be effective against UK virus variant
- New study identifies drugs that are safe to use in COVID-19 treatment
- Regeneron’s antibody cocktail prevents COVID-19 in high-risk patients
- Moderna’s COVID-19 vaccine appears effective against UK and South Africa variants
- AZ refutes reports suggesting its COVID-19 vaccine is less effective in the elderly
- UK study finds antibiotics azithromycin and doxycycline ineffective against COVID-19
- Merck ends its COVID-19 vaccine programme after disappointing early trial results
- Wilmington Healthcare appoints new Head of Digital
PMHub
OPEN Health
OPEN Health is a family of expert practices, working in partnership to drive positive change in healthcare communications & market...
Latest intelligence
- An EU emergency health fund to limit the impact of future crises
- Leading finance experts propose an Emergency Health Financing Facility to limit the impact of future crises on the EU...
- Mistrust in medical research: a patient perspective
- The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
- Real-world evidence: breaking boundaries in rare disease
- Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
Quick links
Infographics
